BRIGHT MINDS BIOSCIENCES INC. (DRUG) Form 6-K — Jun 3, 2026
Bright Minds Biosciences Inc. (DRUG) filed a Form 6-K on June 3, 2026, incorporating its audited consolidated financial statements and management discussion and analysis for the fiscal year ended September 30, 2025. The filing serves as the company’s annual report for U.S. investors, providing a comprehensive view of its financial position and operational results for the completed fiscal year.
Key figures
- Tax Fees2024
- 2500
- Tax Fees2025
- 2500
- Audit Fees2024
- 60500
- Audit Fees2025
- 77000
- Available RSUs
- 686429
- Ceo Salary2023
- 272946
- Ceo Salary2024
- 279119
- Closing Price CAD
- 84.39
- Closing Price USD
- 60.66
- Outstanding RSUs
- 77150
- Available Options
- 403629
- Outstanding Options
- 359950
- Ceo Total Compensation2024
- 450921
- Ceo Total Compensation2025
- 407924
- Weighted Avg Exercise Price RSUs
- 8.8
- Weighted Avg Exercise Price Options
- 23.87
- Auditor
- De Visser Gray LLP
- Ceo Name
- Ian McDonald
- Cfo Name
- Ryan Cheung
- Csio Name
- Jan Pedersen
- Fiscal Year End
- September 30, 2025
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.